Buy Drugs Online:
Drugs Information:
Drugs List

1. Name Of The Medicinal Product

Yasmin, film-coated tablets, 0.03 mg/3 mg

2. Qualitative And Quantitative Composition

Each tablet contains 3 mg drospirenone and 0.030 mg ethinylestradiol.

Excipient: lactose 46 mg.

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Film-coated tablet

Light yellow, round tablet with convex faces, one side embossed with the letters "DO" in a regular hexagon

4. Clinical Particulars

4.1 Therapeutic Indications

Oral contraception

4.2 Posology And Method Of Administration

Route of administration: oral use

How to take Yasmin

The tablets must be taken every day at about the same time, if necessary with a little liquid, in the order shown on the blister pack. One tablet is to be taken daily for 21 consecutive days. Each subsequent pack is started after a 7-day tablet-free interval, during which time a withdrawal bleed usually occurs. This usually starts on day 2-3 after the last tablet and may not have finished before the next pack is started.

How to start Yasmin

No preceding hormonal contraceptive use (in the past month)

Tablet-taking has to start on day 1 of the woman's natural cycle (i.e. the first day of her menstrual bleeding).

• Changing from a combined hormonal contraceptive (combined oral contraceptive (COC), vaginal ring, or transdermal patch)

The woman should start with Yasmin preferably on the day after the last active tablet (the last tablet containing the active substances) of her previous COC, but at the latest on the day following the usual tablet-free or placebo tablet

1. Name Of The Medicinal Product

YARIBA™ TABLETS

2. Qualitative And Quantitative Composition

Kola nut 250 mg.

3. Pharmaceutical Form

Round, slightly glossy film coated tablets.

4. Clinical Particulars

4.1 Therapeutic Indications

A traditional herbal remedy used as a pick-me-up in temporary tiredness.

4.2 Posology And Method Of Administration

To be taken by mouth.

Adults and the elderly: One or two tablets three times a day.

Children under 14: Not recommended.

4.3 Contraindications

Do not use if sensitive to any of the ingredients.

4.4 Special Warnings And Precautions For Use

Keep medicines away from children. Because it contains glucose monohydrate, patients with rare glucose-galactose malabsorption should not take this medicine.

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

None known.

4.6 Pregnancy And Lactation

Not recommended.

4.7 Effects On Ability To Drive And Use Machines

None known.

4.8 Undesirable Effects

None reported.

4.9 Overdose

Occasionally slight insomnia. In emergency withdraw treatment.

5. Pharmacological Properties

5.1 Pharmacodynamic Properties

Kola is a stimulant, with the action of caffeine which it contains.

5.2 Pharmacokinetic Properties

No special information.

5.3 Preclinical Safety Data

No special information.

6. Pharmaceutical Particulars

6.1 List Of

1. Name Of The Medicinal Product

Yeast-Vite

2. Qualitative And Quantitative Composition

Caffeine EP 50.0 MG

Nicotinamide 1.75 MG

Thiamine Hydrochloride (Vitamin B1) 0.167 MG

Riboflavin (Vitamin B2) 0.167 MG

3. Pharmaceutical Form

Tablet

4. Clinical Particulars

4.1 Therapeutic Indications

1. For the relief of fatigue and drowsiness.

2. The maximum daily dose will supply the recommended daily amount of Vitamins B1, B2 and Nicotinamide.

4.2 Posology And Method Of Administration

Adults and Children aged 12 years and over

2 tablets every 3 – 4 hours as required.

Do not exceed 12 tablets in any period of 24 hours.

Not to be given to children under 12 years of age, except on medical advice.

The Elderly

The normal adult dose should be taken.

4.3 Contraindications

Known sensitivity to caffeine. Hypersensitivity to any of the ingredients.

4.4 Special Warnings And Precautions For Use

Label Warnings

Do not exceed the stated dose.

If symptoms persist, consult your doctor.

Keep out of reach of children.

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

Caffeine may enhance the action of Ergotamine. High doses may cause tremor and palpitations. Patients should avoid excessive intake of coffee or tea.

Other drugs which may have their action altered by caffeine are idrocilamide, mexiletine, ciprofloxacin, enoxac

1. Name Of The Medicinal Product

YERVOY

2. Qualitative And Quantitative Composition

Each ml of concentrate contains 5 mg ipilimumab.

One 10 ml vial contains 50 mg of ipilimumab.

One 40 ml vial contains 200 mg of ipilimumab.

Ipilimumab is a fully human anti-CTLA-4 monoclonal antibody (IgG1?) produced in Chinese hamster ovary cells by recombinant DNA technology.

Excipients

Each ml of concentrate contains 0.1 mmol sodium, which is 2.30 mg sodium.

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Concentrate for solution for infusion (sterile concentrate).

Clear to slightly opalescent, colourless to pale yellow liquid that may contain light (few) particulates and has a pH of 7.0 and an osmolarity of 260-300 mOsm/kg.

4. Clinical Particulars

4.1 Therapeutic Indications

YERVOY is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy.

4.2 Posology And Method Of Administration

Treatment must be initiated and supervised by specialist physicians experienced in the treatment of cancer.

Posology

Adults

The recommended induction regimen of YERVOY is 3 mg/kg administered intravenously over a 90-minute period every 3 weeks for a total of 4 doses. Patients should receive the entire induction regimen (4 doses) as tolerated, regardless of the appearance of new lesions or growth of existing lesions. Assessments of tumour response should be conducted only after completion of induction therapy.

Liver functio

1. Name Of The Medicinal Product

YENTREVE* 20mg and 40mg hard gastro-resistant capsules.

2. Qualitative And Quantitative Composition

Each 20mg capsule contains 20mg of duloxetine (as hydrochloride).

Excipients 20mg: Each capsule contains 5.7mg sucrose.

Each 40mg capsule contains 40mg of duloxetine (as hydrochloride).

Excipients 40mg: Each capsule contains 11.5mg sucrose.

For the full list of excipients, see section 6.1.

3. Pharmaceutical Form

Hard gastro-resistant capsule.

The 20mg capsule has an opaque blue body, imprinted with '20mg', and an opaque blue cap, imprinted with '9544'.

The 40mg capsule has an opaque orange body, imprinted with '40mg', and an opaque blue cap, imprinted with '9545'.

4. Clinical Particulars

4.1 Therapeutic Indications

YENTREVE is indicated for women for the treatment of moderate to severe stress urinary incontinence (SUI).

YENTREVE is indicated in adults.

For further information see section 5.1.

4.2 Posology And Method Of Administration

Posology

The recommended dose of YENTREVE is 40mg twice daily, without regard to meals. After 2-4 weeks of treatment, patients should be re-assessed in order to evaluate the benefit and tolerability of the therapy. Some patients may benefit from starting treatment at a dose of 20mg twice daily for two weeks before increasing to the recommended dose of 40mg twice daily. Dose escalation may decrease, though not eliminate, the risk of nausea and dizziness.

A 20 mg capsule is also available. However, limited data are available to support the efficacy of YENTREVE 20mg twice dail

1. Name Of The Medicinal Product

Yellox

2. Qualitative And Quantitative Composition

One ml of solution contains 0.9 mg bromfenac (as sodium sesquihydrate).

One drop contains approximately 33 micrograms bromfenac.

Excipient:

Each ml of solution contains 50 micrograms of benzalkonium chloride.

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Eye drops, solution.

Clear yellow solution.

pH: 8.1-8.5; osmolality: 270-330 mOsmol/kg

4. Clinical Particulars

4.1 Therapeutic Indications

Treatment of postoperative ocular inflammation following cataract extraction in adults.

4.2 Posology And Method Of Administration

Posology

Use in adults, including the elderly

The dose is one drop of Yellox in the affected eye(s) twice daily, beginning the next day after cataract surgery and continuing through the first 2 weeks of the postoperative period.

The treatment should not exceed 2 weeks as safety data beyond this is not available.

Paediatric population

The safety and efficacy of bromfenac in paediatric patients has not been established. No data are available.

Hepatic and renal impairment

Yellox has not been studied in patients with hepatic disease or renal impairment.

Method of administration

For ocular use.

If more than one topical ophtalmic medicinal product is being used, each one should be administered at least 5

1. Name Of The Medicinal Product

0.25 mg vial

1 mg vial

2. Qualitative And Quantitative Composition

0.25 mg vial

Each vial contains 0.25 mg of trabectedin.

1 mg vial

Each vial contains 1 mg of trabectedin.

0.25 mg and 1 mg vials

1 ml of reconstituted solution contains 0.05 mg of trabectedin.

Excipients with known effect:

0.25 mg vial

Each vial contains 2 mg of potassium and 0.1 g of sucrose.

1 mg vial

Each vial contains 8 mg of potassium and 0.4 g of sucrose.

0.25 mg and 1 mg vials

For the full list of excipients, see section 6.1.

3. Pharmaceutical Form

Powder for concentrate for solution for infusion.

White to off-white powder.

4. Clinical Particulars

4.1 Therapeutic Indications

Yondelis is indicated for the treatment of patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.

Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer.

4.2 Posology And Method Of Admi

Yeast Vite

Important information about Yeast Vite Tablets

  • This medicine relieves tiredness and drowsiness.
  • It can be taken by adults, the elderly and children over 12 years.

Do not take….

  • Excessive amounts of tea or coffee when taking this medicine.

Talk to your doctor ….

  • If you are taking any other medicines. See section 2.

Now read the rest of the leaflet before you use this medicine. It includes other information which might be especially important for you.

  • Keep this leaflet. You may need to read it again.
  • Ask your pharmacist if you need any more information or advice.
  • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

What the medicine is for

Yeast Vite Tablets contain caffeine, a mild stimulant and supply the maximum daily dose of vitamins B1, B2 and B3. These ingredients taken together help relieve fatigue (tiredness) and drowsiness.

Before you use this medicine

Do not use the medicine if you have….

  • An allergy to any of the ingredients listed in section 6.

Talk to your doctor or pharmacist if you are taking ….

  • Medic